| 0 (0%) | 12-26 19:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.13  |
1-year : | 7.16 |
| Resists | First : | 5.25 |
Second : | 6.13 |
| Pivot price | 3.76 |
|||
| Supports | First : | 3.84 |
Second : | 2.98 |
| MAs | MA(5) : | 4.59 |
MA(20) : | 3.63 |
| MA(100) : | 3.08 |
MA(250) : | 0 | |
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 97.3 |
D(3) : | 95.7 |
| RSI | RSI(14): 87.5 |
|||
| 52-week | High : | 5.5 | Low : | 2.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LPCN ] has closed above the upper band by 4.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 348.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.25 - 5.27 | 5.27 - 5.29 |
| Low: | 4.52 - 4.53 | 4.53 - 4.55 |
| Close: | 5.2 - 5.23 | 5.23 - 5.26 |
Tue, 16 Dec 2025
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Thu, 20 Nov 2025
Phase 3 Trial of LPCN 1154 for Postpartum Depression Shows Positive Progress - Psychiatric Times
Thu, 06 Nov 2025
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 06 Nov 2025
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PR Newswire
Tue, 04 Nov 2025
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PR Newswire
Tue, 30 Sep 2025
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 5.39e+006 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.25e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -126.7 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 933.5 % |
| Return on Equity (ttm) | -21.5 % |
| Qtrly Rev. Growth | 4.32e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -31.97 |
| EBITDA (p.s.) | 4.19417e+006 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 2.06 |
| Dividend | 0 |
| Forward Dividend | 115270 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|